Surprising Long Term Survival in Glioblastoma Patients Treated with Cannabidiol

Author Info

Rudolf Likar Gerhard Nahler

Corresponding Author

Gerhard Nahler
CIS Clinical Investigation Support GmbH, Vienna, Austria

A B S T R A C T

Glioblastoma multiforme (GBM) is one of the most deadly tumors; even with aggressive radiochemotherapy, mean survival rates are only around 14 to 16 months post diagnose. Here we present the follow-up of 15 patients with GBM that have received concomitant cannabidiol (CBD) in addition to standard therapy, and that have been reported in details two years ago. The survival time of patients is presented together with prognostic factors such as age at diagnose, molecular markers and dose of CBD. The actual median survival time is 28 months, the arithmetic mean is 30.9 months, therefore about three to five times longer than expected. When comparing the group of patients surviving less than 28 months with those who lived longer, we found that all subjects who received a low dose of CBD (200mg per day) were in the group surviving less than 28 months. Apart from the daily dose of CBD, no striking difference was observed for other prognostic factors. It is concluded that CBD contributed to the long term survival of GBM patients, and that this effect depends on the dose.

Article Info

Article Type

Case Report

Publication history

Received: Tue 28, Feb 2023
Accepted: Mon 13, Mar 2023
Published: Mon 20, Mar 2023

Copyright

© 2023 Gerhard Nahler. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.COR.2023.01.05